# DOAC's verlagen risico op hersenbloeding en beroerte bij AF met eerdere ICH — meta-analyse

*geplaatst 2026-08-30 · Atriumfibrilleren · Open heart · doi 10.1136/openhrt-2026-004264 · https://hartvaat.nl/2026/08/21/doac-s-verlagen-risico-op-hersenbloeding-en-beroerte-bij-af-met-eerdere-ich-meta/*

Een systematische review en meta-analyse onderzocht het gebruik van direct werkende orale anticoagulantia (DOAC's) versus vitamine K-antagonisten (VKA's) bij patiënten met atriumfibrilleren en een voorgeschiedenis van intracraniële bloeding. In vijf observationele studies bleken DOAC's geassocieerd met een lager risico op een recidiverende hersenbloeding (HR 0,65) en ischemische beroerte (HR 0,80), hoewel de zekerheid van het bewijs matig tot zeer laag is en gevoeligheidsanalyses de uitkomsten voor beroerte en sterfte minder robuust maakten. Deze bevindingen ondersteunen het gebruik van DOAC's als eerste keuze in deze kwetsbare groep, maar benadrukken dat definitieve richtlijnadviezen wachten op gerandomiseerd onderzoek.

## English: Walking a tightrope: the safety and efficacy of oral anticoagulants in atrial fibrillation patients with prior intracranial haemorrhage: a systematic review and meta-analysis.

A systematic review and meta-analysis evaluated direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation and a history of intracranial haemorrhage. Based on five observational studies, DOACs were associated with a lower risk of recurrent intracranial haemorrhage (HR 0.65) and ischaemic stroke (HR 0.80), although evidence certainty ranged from moderate to very low and sensitivity analyses attenuated the stroke and mortality benefits. While DOACs appear preferable for clinical decision-making in this high-risk population, the authors caution that practice-changing guidelines await prospective randomised trials.

## Abstract (original, from the publication)

INTRODUCTION: The optimal anticoagulation strategy for patients with atrial fibrillation (AF) and prior intracranial haemorrhage (ICH) remains uncertain. Although direct oral anticoagulants (DOACs) have demonstrated a more favourable safety profile than vitamin K antagonists (VKAs) in the general AF population, comparative evidence in patients with previous ICH is limited. METHODS: We conducted a systematic review and meta-analysis comparing DOACs and VKAs in patients with AF and prior ICH. PubMed, Scopus and ScienceDirect were searched from inception to 16 March 2026. Outcomes of interest were ischaemic stroke, recurrent ICH and all-cause mortality. Risk of bias was assessed using Risk of Bias In Non-randomised Studies of Interventions (ROBINS-I) V.2. Pooled HRs with 95% CIs were calculated using random-effects models. RESULTS: Five observational studies were included. Compared with VKAs, DOACs were associated with a lower risk of recurrent ICH (5 studies, HR 0.65, 95% CI 0.53 to 0.79), ischaemic stroke (4 studies, HR 0.80, 95% CI 0.68 to 0.94) and all-cause mortality (3 studies, HR 0.64, 95% CI 0.45 to 0.89). Heterogeneity was absent for ischaemic stroke and recurrent ICH (I²=0%) but substantial for mortality (I²=89%). The recurrent ICH finding remained robust across leave-one-out, Hartung-Knapp-Sidik-Jonkman and overlap-adjusted sensitivity analyses, whereas the ischaemic stroke and mortality estimates lost statistical significance under more conservative methods. CONCLUSION: DOACs appeared favourable over VKAs for recurrent ICH, ischaemic stroke and mortality, but certainty of evidence ranged from moderate to very low. These findings are hypothesis-generating and should inform shared decision-making, not definitive practice change, pending randomised evidence. PROSPERO REGISTRATION NUMBER: CRD420261333839.

Auteurs: Andreas Mercyan Anggitama, Edwin Pranata Laban, Christien Carla Bambuta, Christian Stefanny Gerungan, Arya Taksya Bagaskara, Kristin Purnama Dewi, Ivana Purnama Dewi

---
Bron: Open heart, https://doi.org/10.1136/openhrt-2026-004264. Bijgewerkt 2026-08-23T01:09:25Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.